Sickle Cell Disease (SCD)

Innovating to End the Burden of Sickle Cell Disease Body

At QCIL, we believe no life should be lost to a preventable crisis. In 2026, we commissioned our local Hydroxyurea manufacturing facility and launched Sikurea—ensuring continuous, high-quality treatment reaches the patients who need it most.